Simón C, Frances A, Piquette G N, el Danasouri I, Zurawski G, Dang W, Polan M L
Department of Gynecology and Obstetrics, Stanford University Medical Center, California 94305.
Endocrinology. 1994 Feb;134(2):521-8. doi: 10.1210/endo.134.2.8299552.
We have investigated the relevance of interleukin-1 receptor type I (IL-1R tI) in the implantation process in vivo in a murine model. Indirect immunofluorescence experiments demonstrate that IL-1R tI is located in mouse endometrial lumenal epithelium with increased intensity in the periimplantation period, whereas IL-1 beta staining is located in the mouse placenta. PMSG/human CG (hCG)-stimulated and mated 12-week-old B6C3F-1 female mice were randomly allocated to three groups: A, control noninjected; B, buffer-injected animals; and C, animals injected ip with 20 micrograms recombinant human IL-1 receptor antagonist (rhIL-1ra) every 12 h beginning on pregnancy day 3. Injections were continued until day 9, and animals were killed 12 h after the last injection. Pregnancy rates in the three groups were: noninjected, 58.8% (10 of 17); buffer-injected, 73.7% (14 of 19); rhIL-1ra-injected, 6.7% (1 of 15), P = 0.0001155, Fisher exact test. To rule out the possibility that pregnancy failure was due to an embryotoxic effect of rhIL-1ra, 2-cell mouse embryos (n = 276) were flushed from the same group of animals used for in vivo experiments and cultured with increasing concentrations of rhIL-1ra: 0 microgram/ml (n = 91), 1 microgram/ml (n = 36), 50 micrograms/ml (n = 36), 100 micrograms/ml (n = 52), and 200 micrograms/ml (n = 61) rhIL-1ra. The percentages of 2-cell mouse embryos reaching the blastocyst stage after 72 h in culture were 85.7%, 91.6%, 94.4%, 96%, and 85.2%, respectively. We further cultured these blastocysts for 5 days on fibronectin-coated plates with or without 200 micrograms/ml rhIL-1ra. In both groups, hatching, attachment to fibronectin, outgrowth, and migration were documented to be similar. Furthermore, our longitudinal morphological study of embryonic implantation in control and rhIL-1ra-injected mice shows that the blockade of IL-1R tI interferes with the attachment of mouse blastocysts to maternal endometrium in vivo. In summary, we demonstrate that blockade of maternal endometrial IL-1R tI with IL-1ra prevents implantation in the mouse by interfering with embryonic attachment, without adverse effects on blastocyst formation, hatching, fibronectin attachment, outgrowth, and migration in vitro.
我们在小鼠模型中研究了I型白细胞介素-1受体(IL-1R tI)在体内植入过程中的相关性。间接免疫荧光实验表明,IL-1R tI位于小鼠子宫内膜腔上皮,在植入前期强度增加,而IL-1β染色位于小鼠胎盘。用孕马血清促性腺激素/人绒毛膜促性腺激素(hCG)刺激并交配12周龄的B6C3F-1雌性小鼠,随机分为三组:A组,未注射对照;B组,注射缓冲液的动物;C组,从妊娠第3天开始每12小时腹腔注射20微克重组人白细胞介素-1受体拮抗剂(rhIL-1ra)的动物。注射持续至第9天,在最后一次注射后12小时处死动物。三组的妊娠率分别为:未注射组,58.8%(17只中的10只);注射缓冲液组,73.7%(19只中的14只);注射rhIL-1ra组,6.7%(15只中的1只),P = 0.0001155,Fisher精确检验。为排除妊娠失败是由于rhIL-1ra的胚胎毒性作用的可能性,从用于体内实验的同一组动物中冲洗出2-细胞期小鼠胚胎(n = 276),并用浓度递增的rhIL-1ra进行培养:0微克/毫升(n = 91)、1微克/毫升(n = 36)、50微克/毫升(n = 36)、100微克/毫升(n = 52)和200微克/毫升(n = 61)rhIL-1ra。培养72小时后达到囊胚期的2-细胞期小鼠胚胎百分比分别为85.7%、91.6%、94.4%、96%和85.2%。我们进一步在有或没有200微克/毫升rhIL-1ra的纤连蛋白包被平板上培养这些囊胚5天。在两组中,记录到孵化、与纤连蛋白的附着、生长和迁移情况相似。此外,我们对对照和注射rhIL-1ra小鼠胚胎植入的纵向形态学研究表明,阻断IL-1R tI会干扰小鼠囊胚在体内与母体子宫内膜的附着。总之,我们证明用IL-1ra阻断母体子宫内膜IL-1R tI可通过干扰胚胎附着来阻止小鼠植入,而对体外囊胚形成、孵化、纤连蛋白附着、生长和迁移没有不利影响。